Description
17-AAG is a less toxic and more stable analog of geldanamycin. It is an HSP90 inhibitor that displays a 100-fold higher affinity for HSP90 derived from tumor cells compared to HSP90 from normal cells. 17-AAG inhibits Akt activation and expression in tumors and synergizes with a number of antitumor agents such as taxol, cisplatin, and UCN-014. 17-AAG causes the inactivation, destabilization and eventual degradation of HIF-1α. Inhibitor of telomerase activity. Inducer of apoptosis with antitumor activity. Inducer of macroautophagy